Early animal studies published in the *Journal of Endocrinology* showed that AOD-9604 could stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat creation) in obese Zucker rats
Future work should be focused and lean: enroll truly deficient, higher-risk patients, standardize formulations and dosing, and test event-driven hard endpoints aligned to mechanism, while embedding translational markers to confirm on-target biology
Gallagher JJ, Williams-Bouyer N, Villarreal C, Heggers JP, Herndon DN
Choose the path of science, safety, and sustainable results
Heres everything we know so far about these alternatives: How would oral GLP-1 medications work
For instance, increasing protein intake has been shown to reduce hunger and improve satiety, which may aid in overcoming weight loss stalls